Item 9 Labs Corp.

Equities

INLB

US46564C2035

Healthcare Facilities & Services

Market Closed - OTC Markets Other stock markets 09:49:14 10/06/2024 pm IST			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

2023	Item 9 Labs Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	CI
2023	Douglas Bowden Resigned as Chairman of the Board of Directors of Item 9 Labs Corp, Effective July 18, 2023	CI

Item 9 Labs Corp. Reports Earnings Results for the Full Year Ended September 30, 2019

January 15, 2020 at 03:49 am IST

Item 9 Labs Corp. announced earnings results for the full year ended September 30, 2019. For the full year, the company announced sales was USD 4.933 million compared to USD 1.401 million a year ago. Operating loss was USD 10.141 million compared to USD 653,818 a year ago. Net loss was USD 9.824 million compared to USD 688,721 a year ago. Basic loss per share was USD 0.16 compared to USD 0.01 a year ago.

Latest news about Item 9 Labs Corp.

Item 9 Labs Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	22/23/22	CI
Douglas Bowden Resigned as Chairman of the Board of Directors of Item 9 Labs Corp, Effective July 18, 2023	21/23/21	CI
Douglas Bowden Resign as Interim CEO of Item 9 Labs Corp	21/23/21	CI
Item 9 Labs Corp. Announces Resignation of Shane Evans as A Member of the Board of Directors	28/23/28	CI
Item 9 Labs Corp. cancelled the acquisition of Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc.	25/23/25	CI
Item 9 Labs Corp. Announces Management Changes	23/23/23	CI
Item 9 Labs Corp. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23/23/23	CI
Item 9 Labs Corp. Announces Resignation of Michael Weinberger as Member of the Board of Directors	23/23/23	CI
Item 9 Labs Corp. Announces CEO Changes	23/23/23	CI
Item 9 Labs Corp. Announces the Resignation of Lawrence X. Taylor as Board of Director	13/23/13	CI
Item 9 Labs Releases Latest Limited Edition One-Gram Rosin-Infused Pre-Rolls	10/23/10	CI
Item 9 Labs Corp. Reports Earnings Results for the First Quarter Ended December 31, 2022	15/23/15	CI
Item 9 Labs Corp. Reports Earnings Results for the Full Year Ended September 30, 2022	14/23/14	CI
Item 9 Labs Corp. Auditor Raises 'Going Concern' Doubt	13/23/13	CI
Item 9 Labs Corp. Announces Management Promotions	08/22/08	CI
Item 9 Labs Corp. Announces Resignation of Andrew Bowden as Director	30/22/30	CI
Item 9 Labs Corp. Announce Chief Executive Officer Changes	30/22/30	CI
Item 9 Labs Corp. announced that it expects to receive $25 million in funding from ClearThink Capital Partners, LLC	08/22/08	CI
Item 9 Labs Corp. Accelerates Growth of Unity Rd. Dispensary Franchise	18/22/18	CI
Earnings Flash (INLB) ITEM 9 LABS Reports Q3 Revenue $4.9M	16/22/16	MT
Item 9 Labs Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	16/22/16	CI
Item 9 Labs Corp. Nears Completion of Cannabis Cultivation and Lab Facility in Pahrump, Nevada	23/22/23	CI
Item 9 Labs Chief Strategy Officer Jeffrey Rassas Resigns	04/22/04	MT
Item 9 Labs Corp Announces Resignation of Jeffrey Rassas as the Chief Strategy Officer	04/22/04	CI
Item 9 Labs Corp. signed a definitive agreement to acquire Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. for $21 million.	24/22/24	CI

Chart Item 9 Labs Corp.

Duration

Period

More charts

Company Profile

Item 9 Labs Corp. is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The Company also offers a dispensary franchise model through the national Unity Rd. retail brand. The Company offers approximately 75 active cannabis strains and more than 150 differentiated cannabis vaporizer (vape) products, as well as premium concentrates and Orion vape technologies. The Company's Item 9 Labs brand specializes in select products and user experience across several cannabis categories. The Company operates through two segments: Cultivation and Franchising. Its product lines include Item 9 Labs Flower, Item 9 Labs Concentrates, and Orion 710.

Sector

Healthcare Facilities & Services

More about the company

	1st Jan change	Capi.
ITEM 9 LABS CORP.	0.00%	701
AYR WELLNESS INC.	+6.17%	207M
ASCEND WELLNESS HOLDINGS, INC.	-6.19%	194M
ORGANIGRAM HOLDINGS INC.	+23.26%	160M
IANTHUS CAPITAL HOLDINGS, INC.	-28.57%	120M
JUSHI HOLDINGS INC.	+20.09%	109M
INTERCURE LTD.	+82.31%	103M
THE CANNABIST COMPANY HOLDINGS INC.	-60.43%	82.73M
4FRONT VENTURES CORP.	-11.54%	76.56M
BAKHU HOLDINGS, CORP.	+100.00%	60.26M

Medical Farming

Item 9 Labs Corp.

Equities

INLB

US46564C2035

Healthcare Facilities & Services

Item 9 Labs Corp. Reports Earnings Results for the Full Year Ended September 30, 2019

Latest news about Item 9 Labs Corp.

Chart Item 9 Labs Corp.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Medical Farming